

### REMARKS

The claims have been amended to conform to the election made by applicants. The inventorship does not change.

It is believed that the Office intended to include claims 94-96 in group V rather than groups I-IV since they depend on claim 91. Accordingly, these claims have been cancelled. Applicants have not sorted through the compounds of claims 97-98 at this time; as these claims depend on claim 1 as amended, only those compounds which fall within its amended scope are included in these claims.


Examination on the merits is now requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket No. 391442003700. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: May 29, 2001

By:




Kate H. Murashige  
Registration No. 29,959

Morrison & Foerster LLP  
3811 Valley Centre Drive  
Suite 500  
San Diego, California 92130-2332  
Telephone: (858) 720-5112  
Facsimile: (858) 720-5125

**EXHIBIT A. - VERSION WITH MARKINGS TO SHOW CHANGES MADE**

1. (Twice amended) A compound according to Formula I:



(I)

wherein, W is a nitrogen atom and Y is void or, W is a carbon atom and Y=H;


R<sup>1</sup> to R<sup>7</sup> may be the same or different and are independently hydrogen or straight, branched or cyclic C<sub>1-6</sub> alkyl;

R<sup>8</sup> is an optionally substituted heterocyclic group or an optionally substituted aromatic group


Ar is an aromatic or heteroaromatic ring optionally substituted at single or multiple, non-linking positions with electron-donating or withdrawing groups;

n and n' are independently, 0-2;

X is a group of the formula:



or



wherein, Ring A is an optionally substituted, saturated or unsaturated 5 or 6-membered ring, and P is [an optionally substituted carbon atom,] an optionally substituted nitrogen atom[, sulfur or oxygen atom];

wherein Ring B is an optionally substituted 5 to 7-membered ring;

wherein Ring A or Ring B is bound to group W from any position through group V;

wherein V is a chemical bond or V is a (CH<sub>2</sub>)<sub>n''</sub> group (where n''= 0-2), or V is a C=O group; and

wherein Z is selected from the group consisting of: a hydrogen atom; an optionally substituted C<sub>1-6</sub> alkyl group; a C<sub>0-6</sub> alkyl group substituted with an optionally substituted aromatic or heterocyclic group; an optionally substituted C<sub>0-6</sub> alkylamino or C<sub>3-7</sub> cycloalkylamino group; and an optionally substituted carbonyl group or sulfonyl; and the pharmaceutically acceptable acid addition salts thereof; and

any stereoisomeric forms and mixtures of stereoisomeric forms thereof.

2. (Twice amended) The compound of claim 1, wherein Ring A is selected from the group consisting of: [benzene;] pyridine; pyrimidine; pyrazine; pyridazine; triazine; piperidine; piperazine; imidazole; pyrazole; triazole; oxazole; and thiazole and the optionally substituted forms thereof.

6. (Twice amended) The compound of claim 1, wherein Ring A and Ring B together are optionally substituted [dihydronaphthalene; tetrahydronaphthalene;] dihydroquinoline or tetrahydroquinoline.